Callan Capital LLC Buys Shares of 2,442 Zoetis Inc. (NYSE:ZTS)

Callan Capital LLC bought a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 2,442 shares of the company’s stock, valued at approximately $482,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Bryn Mawr Capital Management LLC grew its holdings in shares of Zoetis by 70.8% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 14,888 shares of the company’s stock worth $2,938,000 after buying an additional 6,170 shares in the last quarter. Jackson Hole Capital Partners LLC purchased a new stake in shares of Zoetis during the fourth quarter worth about $4,148,000. Bank Julius Baer & Co. Ltd Zurich grew its holdings in shares of Zoetis by 12.7% during the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 565,699 shares of the company’s stock worth $111,652,000 after buying an additional 63,950 shares in the last quarter. Sandhill Capital Partners LLC grew its holdings in shares of Zoetis by 2.1% during the fourth quarter. Sandhill Capital Partners LLC now owns 132,606 shares of the company’s stock worth $26,173,000 after buying an additional 2,666 shares in the last quarter. Finally, Abbrea Capital LLC grew its holdings in shares of Zoetis by 5.1% during the fourth quarter. Abbrea Capital LLC now owns 2,065 shares of the company’s stock worth $408,000 after buying an additional 100 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Piper Sandler reiterated an “overweight” rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. The Goldman Sachs Group raised their target price on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Stifel Nicolaus decreased their target price on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Finally, Barclays decreased their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research report on Tuesday. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Zoetis presently has an average rating of “Buy” and an average price target of $218.00.

Zoetis Trading Up 3.3 %

ZTS stock traded up $5.06 during midday trading on Friday, reaching $158.42. 5,236,447 shares of the company’s stock traded hands, compared to its average volume of 3,117,213. The company has a market capitalization of $72.45 billion, a P/E ratio of 31.25, a PEG ratio of 2.31 and a beta of 0.85. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The business has a 50-day moving average price of $171.79 and a two-hundred day moving average price of $179.29.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The business had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. During the same period last year, the firm earned $1.15 earnings per share. The company’s quarterly revenue was up 8.5% on a year-over-year basis. Equities research analysts forecast that Zoetis Inc. will post 5.79 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be paid a dividend of $0.432 per share. The ex-dividend date is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a yield of 1.09%. Zoetis’s dividend payout ratio (DPR) is presently 34.12%.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction on Monday, March 18th. The shares were sold at an average price of $173.33, for a total transaction of $159,983.59. Following the transaction, the executive vice president now directly owns 15,723 shares in the company, valued at approximately $2,725,267.59. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 2,209 shares of company stock worth $371,293 in the last three months. 0.12% of the stock is owned by insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.